Zymeworks BC Inc’s recent filing unveils that its Director EcoR1 Capital, LLC acquired Company’s shares for reported $0.57 million on May 15 ’25. In the deal valued at $11.43 per share,49,502 shares were bought. As a result of this transaction, EcoR1 Capital, LLC now holds 17,877,989 shares worth roughly $227.94 million.
Then, EcoR1 Capital, LLC bought 5,919 shares, generating $69,738 in total proceeds. Upon buying the shares at $11.78, the Director now owns 17,883,908 shares.
Before that, EcoR1 Capital, LLC bought 73,953 shares. Zymeworks BC Inc shares valued at $825,589 were divested by the Director at a price of $11.16 per share. As a result of the transaction, EcoR1 Capital, LLC now holds 17,773,727 shares, worth roughly $226.62 million.
TD Cowen initiated its Zymeworks BC Inc [ZYME] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in mid December from “a Neutral” to “an Overweight”. Leerink Partners also remained covering ZYME and has increased its forecast on November 07, 2024 with a “an Outperform” recommendation from previously “Market perform” rating. Wells Fargo revised its rating on November 01, 2024. It rated ZYME as “an Equal weight” which previously was an “an Overweight”.
Price Performance Review of ZYME
On Friday, Zymeworks BC Inc [NASDAQ:ZYME] saw its stock jump 2.41% to $12.75. Over the last five days, the stock has gained 5.55%. Zymeworks BC Inc shares have fallen nearly -12.91% since the year began. Nevertheless, the stocks have risen 40.11% over the past one year.
